Gastric cancer is the cancer originating in the esophagus, esophagogastric junction and stomach.
Most of gastric cancers are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well differentiated) types.
It is the 4th most common cancer and the 2nd most common cause of cancer-related deaths worldwide.
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction.
Combining the neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios with existing diagnostic methods helps improve early detection of second primary cancers (SPC) after initial gastric cancer (GC), a recent study has found.
Neither gastric cancer nor gastric dysplasia is seen in patients with corpus atrophic gastritis (CAG) characterized at baseline with corpus pseudopyloric metaplasia (PPM) without corpus intestinal metaplasia (IM) because such lesions are consistently associated with corpus IM, reports a study.
Adding the VEGFR*-2 antagonist ramucirumab to paclitaxel extends survival of patients with advanced gastric/GEJ** adenocarcinoma compared with paclitaxel alone, regardless of liver metastasis status, according to a post hoc analysis of the RAINBOW*** trial presented at the ESMO GI 2021 Congress.
Gastroesophageal reflux disease (GERD) may predispose patients to developing other diseases, as reported in a study. For the most part, it puts the whammy on chronic obstructive pulmonary disorder, doubling exacerbations, and raises the risk of oesophageal adenocarcinoma.
Adding nivolumab to chemotherapy in the first-line setting significantly improves survival compared with chemotherapy alone in patients with HER2-negative advanced gastric/gastroesophageal (G/GEJ) cancer or oesophageal adenocarcinoma (EAC), shows the CheckMate 649 study presented at ESMO 2020.
Not only does washing away free tumour cells in the peritoneum with extensive intraoperative peritoneal lavage (EIPL) during gastrectomy confer no survival benefit nor prevent disease recurrence compared with surgery alone, it may come with an increased risk of side effects, according to the phase III EXPEL* study presented at GICS 2020.
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.